We observed similar sensitivity for AML samples carrying FLT3-ITD or activating mutations of JAK2 (Supplementary Fig. 9d and Table 2), suggesting that reported STAT5-activating mutations were not limiting the efficacy of Dynole 34-2. The gene discussed is FLT3; the disease is acute myeloid leukemia.